Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Curie Capital, established in 2018, operates from its headquarters in Amsterdam, Netherlands. This venture capital firm is dedicated to the Life Sciences sector, focusing on early-stage investments in biotechnology, pharmaceuticals, and medical technology. The firm seeks to support talented teams that are developing innovative medical products by offering not only financial backing but also strategic guidance and access to a broad network of industry contacts.
As of now, Curie Capital manages a portfolio of seven companies and adheres to RVO seed capital regulations. The firm primarily invests in companies that are headquartered in the Netherlands and have not raised more than €3.5 million in equity or convertible loans. This focus allows Curie Capital to identify and nurture promising startups within the local ecosystem.
Curie Capital concentrates its investments on Seed and Series A stage companies that are engaged in therapeutics, diagnostics, or class IIb and III medical devices. The firm emphasizes compliance with RVO seed capital regulations, ensuring that its investments are directed towards Dutch companies that meet specific funding criteria. This regulatory adherence not only shapes their investment strategy but also aligns with their commitment to supporting local innovation.
The firm looks for founders who demonstrate strong capabilities and a clear vision for their medical products. Curie Capital values teams that are not only innovative but also capable of navigating the complexities of the life sciences sector. Their investment strategy is designed to provide both capital and strategic guidance, helping portfolio companies to effectively bring their products to market.
Curie Capital's portfolio features a diverse range of companies within the life sciences sector, including:
This portfolio reflects Curie Capital's commitment to investing in companies that are at the forefront of medical innovation, particularly in the fields of biotechnology and healthcare.
Han de Groot, MSc - Partner. Han has extensive experience in venture capital and has led multiple investments in the life sciences sector. He holds a Master's degree in a relevant field and has a strong background in biotechnology.
Mariette van der Velden, MSc - Partner. Mariette specializes in early-stage investments and has a deep understanding of the healthcare market. She has a Master's degree and has been involved in various successful funding rounds.
Thom Frielink, MSc, MBA - Investment Manager. Thom brings a blend of financial acumen and industry knowledge, having worked in both investment banking and venture capital. He holds an MBA and has led several key investments.
Olivier Tak, MD - Junior Partner. Olivier has a medical background and provides insights into clinical development and regulatory affairs. His expertise is invaluable for evaluating healthcare startups.
Markwin Velders, PhD - Advisory Committee Member. Markwin has a PhD in a relevant field and offers strategic guidance based on his extensive research experience in biotechnology.
Mirjam Mol-Arts, MD - Advisory Committee Member. Mirjam's medical expertise enhances the firm's ability to assess healthcare innovations and their market potential.
Helmuth van Es, PhD - Advisory Committee Member. Helmuth provides scientific insights and has a strong background in life sciences research, contributing to the firm's investment decisions.
To pitch Curie Capital, founders should use the contact form available on their website or send an email to dealflow@curiecapital.nl. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, and financial projections. Founders can expect a response within a few weeks, depending on the volume of inquiries.
As of March 2023, Curie Capital continues to expand its portfolio in the life sciences sector, focusing on innovative startups that align with its investment thesis. The firm has made several new investments in early-stage companies, although specific details on these investments have not been disclosed.
Curie Capital remains active in the venture capital space, seeking opportunities that not only promise financial returns but also contribute positively to societal and environmental challenges. The firm is committed to fostering sustainable development through its investment strategy.
What are Curie Capital's investment criteria?
Curie Capital invests in Seed and Series A stage companies primarily in the life sciences sector, focusing on therapeutics, diagnostics, and medical devices. They specifically target companies with a Dutch headquarters that have not raised more than €3.5 million in equity or convertible loans.
How can startups apply or pitch to Curie Capital?
Startups can pitch to Curie Capital through their website at curiecapital.nl or by emailing their deal flow team at dealflow@curiecapital.nl. It is advisable to include a detailed business plan and financial projections in the pitch.
What makes Curie Capital different from other venture capital firms?
Curie Capital distinguishes itself by its focus on the life sciences sector and its commitment to supporting early-stage companies with both capital and strategic guidance. Their expertise in the biotech and healthcare fields allows them to provide valuable insights and connections to their portfolio companies.
What is the geographic scope of Curie Capital's investments?
Curie Capital primarily invests in companies located in the Netherlands, aligning with their focus on supporting local innovation and adhering to RVO seed capital regulations.
What type of post-investment involvement does Curie Capital have?
Curie Capital actively engages with its portfolio companies by providing strategic guidance and access to a broad network of industry contacts, helping them navigate the complexities of the life sciences market.
What is the typical check size for investments made by Curie Capital?
While specific check sizes are not disclosed, Curie Capital focuses on early-stage investments, which typically range from several hundred thousand to a few million euros, depending on the needs of the startup.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.